New data shows SOF-SKN active ingredient efficacy
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Noxopharm Ltd. has released new data demonstrating the efficacy of its SOF-SKN active ingredient in patient samples, particularly for autoimmune diseases like systemic lupus and rheumatoid arthritis. This data supports the potential of the Sofra technology platform for developing new therapeutics beyond its initial application for cutaneous lupus erythematosus.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Noxopharm
- Innovative collaboration further expands Sofra platform
- March 2026 Quarterly Activities Report and Appendix 4C
- Positive SOF-SKN dosing data shows prolonged skin retention
- Noxopharm appoints Dr Olivier Laczka as new CEO
- Resignation of Chief Executive Officer
Later from Noxopharm
- Noxopharm progresses US regulatory strategy
- Noxopharms Sofra assets to be presented at global conference
- New data confirms cancer-fighting potential
- SOF-SKN manufacturing begins to ensure clinical trial readi
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm